Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Kandy Therapeutics Ltd.. (9/27/17). "Press Release: Kandy Therapeutics Launched to Advance a Breakthrough Treatment in Women's Health". Stevenage.

Organisations Organisation Kandy Therapeutics Ltd.
  Organisation 2 Advent Life Sciences LLP
  Group Advent Venture Partners (Advent Ltd.)
Products Product NT-814 (NeRRe Therapeutics / KaNDy Therapeutics)
  Product 2 venture capital
Index terms Index term Kandy Therapeutics–SEVERAL: investment, 201709 seed financing round at spin-out of Kandy Therapeutics from Nerre Therapeutics
  Index term 2 Kandy Therapeutics–Forbion: investment, 201709 seed financing round incl investor Forbion Capital Partners
Persons Person Kerr, Mary (Nerre Therapeutics 201510– CEO before GSK + Advent Life Sciences)
  Person 2 Dukes, Iain D. (OrbiMed 201701 before Merck (US) SVP Business Development + Licensing)
     


First-in-class once daily NT-814 spun out of NeRRe Therapeutics into new company


KaNDy Therapeutics has been launched today to maximise the value of NT-814, a potential breakthrough medicine for the treatment of chronic debilitating Women's Health conditions and is backed by internationally recognised life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed Advisors.

NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal vasomotor symptoms (PMVMS). NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd a separate legal entity.

KaNDy Therapeutics will advance the development of NT-814 into Phase 2b in the lead indication PMVMS while also exploring its potential in other Women's Health conditions. All formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 have been transferred to the new company. KaNDy Therapeutics is led by Managing Director Mary Kerr and chaired by Iain Dukes, Venture Partner at OrbiMed Advisors. The company is based at the Stevenage Bioscience Catalyst in the UK.

NT-814 has significant potential to treat multiple debilitating Women's Health conditions by virtue of the ability to beneficially modulate dysfunctional temperature control and reproductive hormone pathways. NT-814 has already successfully completed a Phase 2a proof of concept study demonstrating its potential to reduce the frequency and severity of PMVMS, and is now being prepared to enter an international Phase 2b study in this anchor indication.

Iain Dukes, Chairman of KaNDy Therapeutics, said, "The formation of KaNDy Therapeutics enables us to maximise the potential of NT-814 in a range of debilitating Women's Health conditions. We believe NT-814 is one of the few true innovations in Women's Health in more than two decades and potentially represents a major breakthrough in areas of significant unmet medical need such as PMVMS. Mary has built up an excellent team who have made substantial progress with NT-814 and we're looking forward to advancing this exciting new product into a Phase 2b programme."

Professor Richard Anderson, Clinical Adviser, University of Edinburgh, commented, "For many women, menopausal symptoms such as hot flashes are debilitating and long-lasting, and can have a major impact on quality of life. As a potential once daily alternative to HRT without the issues surrounding hormone replacement, NT-814 could bring them considerable relief."


Notes for editors


About KaNDy Therapeutics

KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of its unique NK-1,3 receptor antagonist NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions. NT-814 is in development initially as a non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms (PMVMS).

PMVMS affect up to 75% of peri-menopausal women. Symptoms last for 1-2 years after menopause in most women, but may continue for up to 10 years or longer in others. Approximately 20% of women will have debilitating symptoms. Hot flashes are the primary reason women seek medical care at menopause. Hot flashes not only disturb women at work and interrupt daily activities, but also have a detrimental effect on sleep. Post-menopausal vasomotor symptoms are experienced by millions of women globally on a daily basis.

The company is led by an experienced management team including Dr Mary Kerr (Managing Director), formerly SVP and Global Franchise lead at GSK and Dr Mike Trower (CSO/COO), formerly VP & Head of the External Drug Discovery Group in the Neurosciences CEDD at GSK and Dr Steve Pawsey (CMO) formerly at Circassia and Vernalis.

KaNDy Therapeutics was spun out of NeRRe Therapeutics in September 2017, and is backed by internationally recognised life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed Advisors. KaNDy Therapeutics is based at Stevenage Bioscience Catalyst. You can find more information about KaNDy Therapeutics at http://www.kandytherapeutics.com.


For further information, please contact:

Mary Kerr, Managing Director of KaNDy Therapeutics
Tel: +44-1438-906960
Email: info@kandytherapeutics.com

   
Record changed: 2018-01-27

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Kandy Therapeutics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top